Mobile

A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagon...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-004140-23

A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of three dose levels of atacicept in the treatment of signs and symptoms of subjects with active rheumatoid arthritis (RA) who have had an inadequate response to previous TNFalfa antagonist therapy.

Critère d'inclusion

  • Rheumatoid Arthritis

Liens